The significance and clinical utility of the detection of primary malignant circulating prostate cells: a review of the evidence

Abstract

Primary malignant circulating prostate cells (CPCs) are those detected in blood before definitive treatment for prostate cancer. CPCs can be detected in men with benign prostate disease; however, some methods to distinguish between benign and malignant prostate cells have to be validated. This study presents a review of the subject, including theoretical considerations for the selection of markers to detect them, the different methods used, and the utility of their detection in identifying men with prostate cancer and as a prognostic factor.

Keywords

Prostate cancer / circulating prostate cells / cancer detection / prognostic factor

References

[1] Jemal A,Ward E,Xu J,Thun MJ.Cancer statistics..CA Cancer J Clin2006;56:106-30

[2] Draisma G,Tsodikov A,Wever E,Feuer E.Lead time and over-diagnosis in prostate-specific antigen screening: importance of methods and context..J Natl Cancer Inst2009;101:374-83 PMCID:PMC2720697

[3] Andiole GL,Grubb RL3rd,Chia D,Fouad MN,Kvale PA,Weissfeld JL,O'Brien B,Rathmell JM,Hayes RB,Izmirlian G,Pinsky PF,Gohagan JK.Mortality results from a randomized prostate cancer screening trial..N Eng J Med2009;360:1310-9 PMCID:PMC2944770

[4] Schroder FH,Roobol MJ,Ciatto S,Kwiatkowski M,Lilja H,Denis LJ,Berenguer A,Bangma CH,Villers A,van der Kwast T,Moss SM,Auvinen A.Screening and prostate cancer mortality in a randomized European study..N Eng J Med2009;360:1320-8

[5] Carter HB,Barry MJ,Freedland SJ,Holmberg L,Konety BR,Penson DF.Early detection of prostate cancer: AUA guideline..J Urol2013;190:419-26 PMCID:PMC4020420

[6] Smith DS,Catalona WJ.The early detection of prostate carcinoma with prostate specific antigen: the Washington University experience..Cancer1997;80:1852-6

[7] Belbase NP,Pokharel PK,Lamsal M.Prostate cancer screening in a healthy population cohort in Eastern Nepal: an explanatory trial study..Asian Pac J Cancer Prev2013;14:2835-8

[8] Lalitha K,Pruthvish S,Murthy NS.Estimation of time trends of incidence of prostate cancer: an Indian scenario..Asian Pac J Cancer Prev2012;13:6245-50

[9] Anastasiadis E,Emberton M.Hospital admissions after TRUS biopsy of the prostate in men diagnosed with prostate cancer: a database analysis in England..Int J Urol2015;22:181-6

[10] Dall`Era MA,Chan JM,Albertsen PC,Warlick CA,Bailey DEJr,Kantoff PW.Active surveillance for early stage prostate cancer: review of the current literature..Cancer2008;112:1650-9

[11] Warlick C,Landis P,Carter HB.Delayed versus immediate surgical intervention and prostate cancer outcome..J Natl Cancer Inst2006;98:355-7 PMCID:PMC3477641

[12] Wilt TJ,Jones KM,Aronson WJ,Gingrich JR,Gilhooly P,Nsouli I,Cartagena R,Roehrborn C,Blank W,Andriole GL,Wheeler T.Radical prostatectomy versus observation for localized prostate cancer..N Eng J Med2012;367:203-13 PMCID:PMC3429335

[13] Epstein JI,Carmichael M.Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer..JAMA1994;271:368-74

[14] Patel MI,Lopez-Corona E,Wheeler T.An analysis of men with clinically localized prostate cancer who deferred definitive treatment..J Urol2004;171:1520-4

[15] Klotz L.Active surveillance versus radical treatment for favorable risk localized prostate..Curr Treat Options Oncol2006;7:355-62

[16] Carter HB,Landis P.Expectant management of non-palpable prostate cancer with curative intent: preliminary results..J Urol2002;167:1231-4

[17] Sheridan TB,Wang W,Epstein JI.Change in prostate cancer grade over time in men followed expectantly for stage T1c disease..J Urol2008;179:901-4 PMCID:PMC4251426

[18] Berglund RK,Vora KC,Eastham JA.Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance..J Urol2008;180:1964-7 PMCID:PMC2919316

[19] Pound CR,Eisenberger MA,Pearson JD.The natural history of progression after PSA elevation following radical prostatectomy..JAMA1999;281:1591-7

[20] Amling CL,Bergstrahl EJ,Slezak J.Long term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years..J Urol2000;164:101-5

[21] Moreno JG,Fischer R,Vihko P,Gomella LG.Detection of hematogenous micrometastasis in patients with prostate cancer..Cancer1992;52:6110-2

[22] Joosse SA,Pantel K.Biology, detection, and clinical implications of circulating tumor cells..EMBO Mol Med2015;7:1-11 PMCID:PMC4309663

[23] Murray NP,Orellana N,Due-as R.Expression of P504S and matrix metalloproteinase-2 in circulating prostate cells disseminated as a result of transrectal ultrasound guided biopsy as determined by immunocytochemistry: clinical implications..ArchEsp Urol2015;68:474-81

[24] Chaffer CL.A perspective on cancer cell metastasis..Science2011;331:1559-64

[25] Jaggi M,Baker JJ,Galich A.Aberrant expression of E-cadherin and beta-catenin in human prostate cancer..Urol Onc2005;23:402-6

[26] Umbas R,AaldersTW,Karthaus HF,Debruyne FM.Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer..Cancer Res1992;52:5104-9

[27] Pontes JJr,Borra PM,Ribeiro-Filho LA.E-cadherin and beta-catenin loss of expression related to bone metastasis in prostate cancer..Appl Immunohistochem Mol Morphol2010;18:179-84

[28] Murant SJ,Stower M,Cussenot O.Co-ordinated changes in expression of cell adhesion molecules in prostate cancer..Eur J Cancer1997;33:263-71

[29] Alberti I,Barbesino M,Pisciotta L,Nicolò G,Galli S,Balbi C.Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer..J Cell Biochem2000;79:471-85

[30] Chambers AF.Changing views of the role of matrix metalloproteinases in metastasis..J Natl Cancer Inst1997;89:1260-70

[31] Stearns ME.Immunohistochemical studies of activated matrix metalioproteinase-2 (MMP-2a) expression in human prostate cancer..Oncol Res1996;8:63-7

[32] Wood DP.Presence of circulating prostate cells in the bone marrow of patients undergoing radical prostatectomy is predictive of disease-free survival..J Clin Oncol1997;15:3451-7

[33] Kuniyasu H,Johnston D,Tahara E,Pettaway CA.Relative expression of type IV collagenase, E-cadherin, and vascular endothelial growth factor/vascular permeability factor in prostatectomy specimens distinguishes organ-confined from pathologically advanced prostate cancers..Clin Cancer Res2000;6:2295-308

[34] Ross JS,Sheehan CE,Kaufman RAJr.rognostic significance of matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression in prostate cancer..Mod Pathol2003;16:198-205

[35] Trudel D,Meyer F,Têtu B.Significance of MMP-2 expression in prostate cancer: an immunohistochemical study..Cancer Res2003;63:8511-5

[36] Murray NP,Orellana N,Due-as R.Expression of P504S and matrix metalloproteinase-2 in circulating prostate cells disseminated as a result of transrectal ultrasound guided biopsy as determined by immunocytochemistry: clinical implications..Arch Esp Urol2015;68:474-81

[37] Friedlander TW,Dong H,Weinberg V,Zhao Q,Ryan CJ,Paris PL.Detection and characterization of invasive circulating tumor cells derived from men with metastatic castration-resistant prostate cancer..Int J Cancer2014;134:2284-93

[38] Armstrong AJ,Oltean S,Bitting RL,Herold CI,George DJ.Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers..Mol Cancer Res2011;9:997-1007 PMCID:PMC3157566

[39] Chen CL,Osmulski P,Wang CM,Chang TC,Kumar AP,Gaczynska ME,Huang TH.Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer..Prostate2013;73:813-26 PMCID:PMC4882087

[40] Ocana OH,Fabra A,Acloque H,Barrallo-Gimeno A,Nieto MA.Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer Prrx1..Cancer Cell2012;22:709-24

[41] Tsai JH,Murphy DA,Yang J.Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis..Cancer Cell2012;22:725-36 PMCID:PMC3522773

[42] Tsuji T,Shima K,Katsurano M,Hu GF.Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth..Cancer Res2008;68:10377-86 PMCID:PMC2605670

[43] Celia-Terrassa T,Mateo F.Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, Lozano JJ, Estarás C, Ulloa C, álvarez-Simón D, Milà J, Vilella R, Paciucci R, Martínez-Balbás M, de Herreros AG, Gomis RR, Kang Y, Blanco J, Fernández PL, Thomson TM. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells..J Clin Invest2012;122:1849-68 PMCID:PMC3366719

[44] Fidler IJ.Metastasis results from preexisting variant cells within a malignant tumor..Science1977;197:893-5

[45] Baccelli I,Riethdorf S,Schillert A,Klein C,Bäuerle T,Holland-Letz T,Sprick M,Marmé F,Pantel K,Trumpp A.Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay..Nat Biotechnol2013;31:539-44

[46] Bednarz-Knoll N,Pantel K.Plasticity of disseminating cancer cells in patients with epithelial malignancies..Cancer Metastasis Rev2012;31:673-87

[47] Tam WL.The epigenetics of epithelial-mesenchymal plasticity in cancer..Nat Med2013;19:1438-49 PMCID:PMC4190672

[48] Todenhöfer T,Feyerabend S,Mischinger J,Gerber V,Schilling D,Stenzl A.Preliminary experience on the use of the Adnatest® system for detection of circulating tumor cells in prostate cancer patients..Anticancer Res2012;32:3507-13

[49] Alix-Panabières C.Challenges in circulating tumor cell research..Nat Rev Cancer2014;14:623-31

[50] Trzpis M,de Leij LMFH.Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule..Am J Pathol2007;171:386-95 PMCID:PMC1934518

[51] Fidler IJ.Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2′-deoxyuridine..J Natl Cancer Inst1970;45:773-82

[52] Liotta LA,Kleinerman J.The significance of hematogenous tumor cell clumps in the metastatic process..Cancer Res1976;36:889-94

[53] Carvalho FL,Antonarakis ES,Douglas N,Matsui W.Tumorigenic potential of circulating prostate tumor cells..Oncotarget2013;4:413-21 PMCID:PMC3717304

[54] Smerage JB,Doyle GV,Paoletti C,Miller MC,Chianese DA,Terstappen LW.Monitoring apoptosis and Bcl-2 on circulating tumor cells in patients with metastatic breast cancer..Mol Oncol2013;7:680-92 PMCID:PMC5528485

[55] Douma S,Zevenhoven J,Van Garderen E.Suppression of anoikis and induction of metastasis by the neurotrophic receptor TrkB..Nature2004;430:1034-9

[56] Steinert G,Niemietz T,García SA,Voigt A,Benner A,Rahbari NN,Stoecklein NH,Koch M.Immune escape and survival mechanisms in circulating tumor cells of colorectal cancer..Cancer Res2014;74:1694-704

[57] Liu Q,Zhao Y.Myeloid derived suppressor cells (MDSC) facilitate distant metastasis of malignancies by shielding circulating tumor cells (CTCs) from immune surveillance..Med Hypothesis2016;87:34-9

[58] Placke T,Schaller M,Rammensee HG,Salih HR.Platelet derived MHC class I confers a pseudo-normal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells..Cancer Res2012;72:440-8

[59] Parkinson DR,Petty BG,Cristofanilli M,Hayes DF,Kumar P,Liu MC,Mikulski S,Pantel K,Punnoose EA,Schade AE,Sigman CC.Considerations in the development of circulating tumor cell technology for clinical use..J Translat Med2012;10:138 PMCID:PMC3478228

[60] Panteleakou Z.Sourla A, Pissimissis N, Polyzos A, Deliveliotis C, Koutsilieris M. Detection of circulating tumor cells in prostate cancer patients: methodological pitfalls and clinical relevance..Mol Med2009;15:101-14 PMCID:PMC2600498

[61] Brandt B,Griwatz C,Brinkmann O,Assmann G.Isolation of prostate-derived single cells and cell clusters from human peripheral blood..Cancer Res1996;56:4556-61

[62] Mu Z,Ye Z,Civan J,Palazzo JP,Li B,Jiang J,Yang H.Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer..Breast Cancer Res Treat2015;154:563-71

[63] Gertler R,Fuehrer K,Nekarda H.Detection of circulating tumor cells in blood using an optimized density gradient centrifugation..Recent Results Cancer Res2003;162:149-55

[64] Rosenberg R,Friederichs J,Dahm M,Thorban S,Siewert JR.Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood..Cytometry2002;49:150-8

[65] Seal SH.A sieve for the isolation of cancer cells and other large cells from blood..Cancer1964;17:637-42

[66] Plaks V,Werb Z.Cancer. Circulating tumor cells..Science2013;341:1186-8 PMCID:PMC3842225

[67] De Giorgi V,Salvianti F,Orlando C,Pazzagli M.Circulating benign nevus cells detected by ISET technique: warning for melanoma molecular diagnosis..Arch Dermatol2010;146:1120-4

[68] Rhim AD,Santana SM,Saha TN,Maggs LR,Ginsberg GG,Chandrasekhara V,Ahmad N,Kirby BJ.Detection of circulating pancreas epithelial cells in patients with pancreatic cystic lesions..Gastroenterology2014;146:647-51 PMCID:PMC4514438

[69] Allard WJ,Miller MC,Connelly MC,Tibbe AG,Terstappen LW.Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases..Clin Cancer Res2004;10:6897-904

[70] Pantel K,Nocca D,Vendrell JP,Riethdorf S.Circulating epitelial cells in patients with benign colon diseases..Clin Chem2012;58:936-40

[71] Stott SL,Tsukrov DI,Miyamoto DT,Rothenberg SM,Smas ME,Floyd FPJr,Lord JB,Springer S,Nagrath S,Lee RJ,Maheswaran S,Toner M.Isolation of circulating tumor cells using a microvortex generating herring bone-chip..Proc Natl Acad Sci U S A2010;107:18392-7 PMCID:PMC2972993

[72] Chinen LT,Rocha BM,Abdallah EA,Mingues NB,Maciel MS,Dettino AL,Paterlini-Bréchot P.Cytokeratin based CTC counting unrelated to clinical follow up..J Thorac Dis2013;5:593-9 PMCID:PMC3815714

[73] Liu Z,Klopocki E,Tinhofer I,Keilholz U.Negative enrichment by immunomagnetic-nanobeads for unbiased characterization of circulating tumor cells from peripheral blood of cancer patients..J Transl Med2011;9:70 PMCID:PMC3119001

[74] Borgen E,Nesland JM,Beiske K,Diel I,Theocharous P,Smith BM,Marolleau JP,Pantel K.Standardization of the immunocytochemical detection of cancer cells in BM and blood. I. Establishment of objective criteria for the evaluation of immunostained cells..Cytotherapy1999;1:377-88

[75] Murray NP,Badinez L,Badinez O,Reyes E.P504S expressing circulating prostate cells as a marker for prostate cancer..Oncol Reports2010;24:687-92

[76] Murray NP,Ruiz A.Diagnostic yield of primary circulating tumor cells in women suspected of breast cancer: the BEST (Breast Early Screening Test) study..Asian Pac J Cancer Prev2015;16:1929-34

[77] Zhou M,Kleer CG,Rubin MA.Alpha-methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions..Am J of Surg Pathol2002;26:926-31

[78] Beach R,De Peralta-Venturina MN,Yaziji H,Grignon DJ,Amin MB.P504S immunohistochemical detection in 405 prostatic specimens including 376 18-gauge needle biopsies..Am J Surg Pathol2002;26:1588-96

[79] Murray NP,Badinez L,Fuentealba C,Porcell J.Circulating prostate cells found in men with benign prostate disease are p504s negative: clinical implications..J Oncol2013;2013:165014 PMCID:PMC3652185

[80] Mu Z,Ye Z,Civan J,Palazzo JP,Li B,Jiang J,Yang H.Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer..Breast Cancer Res Treat2015;154:563-71

[81] Paoletti C,Muniz MC,Aung K,Brown ME,Irvin WJJr,Liu MC,Nangia JR,Traina TA,Van Poznak CH,Forero-Torres A,Translational Breast Cancer Research Consortium (TBCRC).Significance of circulating tumor cells in metastatic triple-negative breast cancer patients within a randomized, phase ii trial: TBCRC 019..Clin Cancer Res2015;21:2771-9 PMCID:PMC5521206

[82] Molloy TJ,Helgason HH,Hauptmann M,Schellens JH.A multimarker qPCR-based platform for the detection of circulating tumor cells in patients with early-stage breast cancer..Br J Cancer2011;104:1913-9 PMCID:PMC3111197

[83] Ignatiadis M,Ntoulia M,Apostolaki S,Chlouverakis G,Lianidou E,Mavroudis D.Prognostic value of the molecular detection of circulating tumor cells using a multi-marker reverse transcription-PCR assay for cytokeratin 19, mammaglobin A, and HER2 in early breast cancer..Clin Cancer Res2008;14:2593-600

[84] Strati A,Parisi C,Mavroudis D,Lianidou E.(2011) Gene expression profile of circulating tumor cells in breast cancer by RT-PCR..BMC Cancer2011;11:422 PMCID:PMC3224356

[85] Obermayr E,Tea MK,Krainer M,Sehouli J,Horvat R,Tong D.Assessment of a six-gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients..BMC Cancer2010;10:666 PMCID:PMC3013085

[86] Davis JW,Kumar VS,McCormack R,Handy B,Babaian RJ.Circulating tumor cells in peripheral blood samples from patients with increased serum prostate specific antigen: initial results in early prostate cancer..J Urol2008;179:2187-91

[87] Thalgott M,Mauerer T,Eiber M,Heck MM,Nawroth R,Retz M.Detection of circulating tumor cells in different stages of prostate cancer..J Cancer Res Clin Oncol2013;139:755-63

[88] Helo P,Danila DC,Gonzalez-Espinoza R,Koscuiszka M,Pettersson K,Steuber T,Guillonneau BD,Scardino PT,Scher HI.Circulating prostate tumor cells detected by RT-PCR in men with localized or castration refractory prostate cancer: concordance with CellSearch assay and association with bone metastasis and survival..Clin Chem2009;55:765-73 PMCID:PMC2782624

[89] Loh J,Lehman M,Pryor D,Nelson C.Circulating tumor cell detection in high risk non-metastatic prostate cancer..J Cancer Res Clin Oncol2014;140:2157-62

[90] Kolostova K,Schraml J,Matkowski R,Bobek V.CTCs in localized prostate cancer: isolation, cultivation in vitro and relationship to T-stage and Gleason score..Anticancer Res2014;34:3641-6

[91] Stott SL,Nagrath S,Miyamoto DT,Inserra EJ,Springer S,Moore AL,Kempner ME,Wu CL,Smith MR,Sequist LV,Haber DA.Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer..Sci Transl Med2010;2:25ra23 PMCID:PMC3141292

[92] Fizazi K,Chauveinc L,De Crevoisier R,Cathelineau X,Vallancien G,Soria JC.High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity..Ann Oncol2007;18:518-21

[93] Murray NP,Fuentealba C.Efficacy of using sequential primary circulating prostate cell detection for initial prostate biopsy in men suspected of prostate cancer..Asian Pac J Cancer Prev2016;17:3385-90

[94] Murray NP,Orellana N,Due-as R.A comparative performance analysis of total PSA, percentage free PSA, PSA velocity, and PSA density versus the detection of primary circulating prostate cells in predicting initial prostate biopsy findings in Chilean men..Biomed Res Int2014;2014:676572 PMCID:PMC4101233

[95] Murray NP,Fuentealba C,Morales F.Comparison of the formula of PSA, age, prostate volume and race versus PSA density and the detection of primary malignant circulating prostate cells in predicting a positive initial prostate biopsy in Chilean men with suspicion of prostate cancer..Asian Pac J Cancer Prev2015;16:5365-70

[96] Murray NP,Fuentealba C,Jacob O.Head to Head comparison of the Montreal Nomagram with the detection of primary malignant circulating prostate cells to predict prostate cancer at initial biopsy in Chilean men with suspicion of prostate cancer..Urol Onc2015;33:e19-25

[97] Murray NP,Fuentealba C,Jacob O.Primary circulating prostate cells are not detected in men with low grade small volume prostate cancer..J Oncol2014;2014:612674 PMCID:PMC4152931

[98] Ennis RD,de Vries GM,O'Toole KM,Buttyan R,Schiff PB.Detection of circulating prostate carcinoma cells via an enhanced RT-PCR assay in patients with early stage prostate carcinoma. Independence from other pretreatment characteristics..Cancer1997;79:2402-8

[99] Eschwège P,Droupy S,Gala JL,Conti M,Loric S.Prognostic value of prostate circulating cells detection in prostate cancer patients: a prospective study..Br J Cancer2009;100:608-10 PMCID:PMC2653745

[100] Murray NP,Reyes E,Jacob O.Outcome of radical prostatectomy in primary circulating prostate cell negative prostate cancer..Ecancermedicalscience2016;10:671 PMCID:PMC5014557

[101] Meyer CP,Tennstedt P,Schlomm T,Riethdorf S.Limited prognostic value of preoperative circulating tumor cells for early biochemical recurrence in patients with localized prostate cancer..Urol Oncol2016;34:235.e11-6

[102] Murray NP,Fuentealba C,Reyes E,Orellana S.Limited improvement of incorporating primary circulating prostate cells with the CAPRA score to predict biochemical failure-free outcome of radical prostatectomy for prostate cancer..Urol Oncol2016;34:430.e17-25